Bio-Rad posts $715.8 million Q4 net loss as revenue falls 2.0% and restructuring begins
Bio-Rad reported fourth-quarter 2024 net sales of $667.5 million, down 2.0%, and income from operations of $58.4 million, down from $95.3 million a year earlier. A $976.5 million loss from changes in the fair market value of equity securities and a loan receivable, which the company said substantially contributed to the result, drove a net loss of $715.8 million, and the company also began a restructuring that it expects to cost $45 million to $50 million. Shareholders also face a pending Stilla Technologies acquisition and 2025 guidance for non-GAAP currency-neutral revenue growth of 1.5% to 3.5%.
Key points
- Q4 2024 net sales were $667.5 million, down 2.0% from $681.2 million; Life Science segment sales fell 5.5% to $275.0 million.
- Q4 2024 net loss was $715.8 million, or $25.57 per diluted share, versus net income of $349.7 million in Q4 2023.
- Restructuring plan initiated February 7, 2025, to eliminate about 5% of the workforce, with total costs estimated at $45 million to $50 million, $30 million to $35 million of which is expected in Q1 2025.
- Company made a binding offer to buy all equity interests in Stilla Technologies, a French corporation, and expects 2025 non-GAAP operating margin of 13.0% to 13.5%.
The filing
Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 13, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.